(A) Presence of PD-1, its ligands PD-L1 and PD-L2, and the phosphatases SHP-1, SHP-2, and SHP-2-like (SHP-2L) in representative jawed vertebrates, including sharks, ray-finned fish, amphibians, and ...

LAG-3 and TIGIT expression may predict skin melanoma progression and survival. Discover how these immune markers could shape future therapies. Read more.

A simplified schematic illustrating how cancer cells evade immune attack by expressing PD-L1, which binds to PD-1 on T cells and suppresses their activity. The figure also shows how immune checkpoint ...

Cancer immunotherapy drugs called immune checkpoint inhibitors take the brakes off the body’s immune system, allowing it to find and attack cancer cells. One such checkpoint protein, programmed cell ...

Phase I Clinical Trial Evaluating Safety, Tolerability, and Early Activity of Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF-Altered Solid Tumors or NRAS-Mutant Melanoma PD-L1 ...

Putting Methylphenidate for Cancer-Related Fatigue to Rest? While immune checkpoint inhibitors (ICIs) have improved outcomes for patients with non–small cell lung cancer (NSCLC), most patients ...

BRIDGEWATER, NJ / ACCESS Newswire / April 7, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today ...

Pfizer PFE announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, from Chinese biotech, 3SBio. 3SBio ...